Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 12, 2019

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
NK/T Cell Lymphoma
Interventions
DRUG

IV Nivolumab

240mg every 2 weeks.

DRUG

IV Nivolumab

Initial treatment dose is 240mg every 2 weeks for 4 doses. Dose changes to 360mg every 3 weeks when given with GDP/L-aspa. Maintenance treatment dose is 240mg every 2 weeks.

DRUG

IV Gemcitabine

800mg/m2 on Days 1 and 8 every 21 days

DRUG

IV Cisplatin

20mg/m2 on Day 1 to 4 every 21 days

DRUG

IV/PO Dexamethasone

10mg on Days 1 to 4 every 21 days

DRUG

IV L-asparaginase

6000 Units/m2 on Days 2 to 8 every 21 days

Trial Locations (1)

Unknown

National Cancer Centre Singapore, Singapore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Cancer Centre, Singapore

OTHER